SAB Biotherapeutics (SABS) has released an update.
The Company has been notified by Nasdaq on January 23, 2024, that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), and as a result, Nasdaq considers the matter closed.
For further insights into SABS stock, check out TipRanks’ Stock Analysis page.
